Search for a clinical trial
Other search option(s)
28 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Study involving ERN members in at least two Member States = 
National clinical trial(s)
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - FR
Institution: Information not provided - FR
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - DE
Institution: Information not provided - DE
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - ES
Institution: Information not provided - ES
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas - GB
Institution: Information not provided - UK
UNITED KINGDOM
Lancashire
PRESTON
POUT: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer
Royal Preston Hospital
Rosemere Cancer Centre
FRANCE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment-FR
Institution: Information not provided - FR
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
LuPARP - Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours - SE
Institution: Information not provided - SE
FRANCE
BOURGOGNE-FRANCHE-COMTE
BESANÇON
EPICentro : Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors (Phase II)
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCE
ILE-DE-FRANCE
VILLEJUIF
AcSé : Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (Phase II)
CLCC Institut Gustave Roussy
Département d'Innovation Thérapeutique et d'Essais Précoces
ITALY
EMILIA ROMAGNA
MELDOLA
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS)
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
Dipartimento di Oncologia ed Ematologia Clinica e Sperimentale
ITALY
EMILIA ROMAGNA
MELDOLA
LUTHREE - Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
ITALY
PUGLIA
SAN GIOVANNI ROTONDO
Bevacizumab in association with slow-relapsing Octreotide and Capecitabine in patients with well-differentiated neuroendocrine neoplasia and in advanced phase (Phase II)
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe - ES
Institution: Information not provided - ES
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Institution: Information not provided - US
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie-Oncologie thoracique
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O.C. Oncoematologia, Trapianto Emopoietico e Terapie Cellulari
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants -ES
Institution: Information not provided - ES
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
Multinational clinical trial(s)
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
DAREON(TM)-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment (Phase IV)
Institution: Information not provided - US
FRANCE
ILE-DE-FRANCE
RUEIL-MALMAISON
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours
Advanced Accelerator Applications SA
Advanced Accelerator Applications
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US